Research graph
References from Clinical Utility of a Type 1 Diabetes Genetic Risk Score Measured as Part of MODY Genetic Testing. Local targets link to admitted publications; unresolved targets remain external evidence.
Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients
10.2337/dc17-0224 · 2017 · External reference
Maturity-onset diabetes of the young (MODY): how many cases are we missing?
10.1007/s00125-010-1799-4 · 2010 · External reference
Precision diabetes: learning from monogenic diabetes
10.1007/s00125-017-4226-2 · 2017 · External reference
The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes
10.1007/s00125-011-2418-8 · 2012 · External reference
How do I diagnose maturity onset diabetes of the young in my patients?
10.1111/cen.14744 · 2022 · External reference
Unresolved reference
External reference
Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors
10.2337/dc14-0871 · 2015 · External reference
The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
10.1093/cei/uxac087 · 2022 · External reference
Gene panel sequencing of patients with monogenic diabetes brings to light genes typically associated with syndromic presentations
10.2337/db21-0520 · 2022 · External reference
Syndromic monogenic diabetes genes should be tested in patients with a clinical suspicion of maturity-onset diabetes of the young
10.2337/db21-0517 · 2022 · External reference
A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults
10.2337/dc15-1111 · 2016 · External reference
Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes
10.2337/db15-1690 · 2016 · External reference
Zinc transporter 8 autoantibodies (ZnT8A) and a type 1 diabetes genetic risk score can exclude individuals with type 1 diabetes from inappropriate genetic testing for monogenic diabetes
10.2337/dc18-0373 · 2019 · External reference
Methods for quick, accurate and cost-effective determination of the type 1 diabetes genetic risk score (T1D-GRS)
10.1515/cclm-2019-0787 · 2020 · External reference
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
10.1038/nature05911 · 2007 · External reference
Improved genetic testing for monogenic diabetes using targeted next-generation sequencing
10.1007/s00125-013-2962-5 · 2013 · External reference
Population labels can be generated directly from targeted next-generation sequencing data
10.21203/rs.3.rs-5282595/v1 · External reference
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
10.1038/gim.2015.30 · 2015 · External reference
Unresolved reference
External reference
Estimating disease prevalence in large datasets using genetic risk scores
10.1038/s41467-021-26501-7 · 2021 · External reference
The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes
10.1007/s00125-022-05823-1 · 2023 · External reference
Investigating misclassification of type 1 diabetes in a population-based cohort of British Pakistanis and Bangladeshis using polygenic risk scores
10.1038/s41598-024-80348-8 · 2025 · External reference
Genetics of circulating proteins in newborn babies at high risk of type 1 diabetes
10.1038/s41467-025-58972-3 · 2025 · External reference
Circulating pancreatic enzyme levels are a causal biomarker of type 1 diabetes
10.1101/2024.08.08.24311619 · External reference
Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
10.1186/s13073-022-01117-8 · 2022 · External reference
Polygenic risk scores in the clinic: translating risk into action
10.1016/j.xhgg.2021.100047 · 2021 · External reference
Clinical use of polygenic risk scores: current status, barriers and future directions
10.1038/s41576-025-00900-8 · 2026 · External reference
Development of a clinical polygenic risk score assay and reporting workflow
10.1038/s41591-022-01767-6 · 2022 · External reference
Epidemiology and determinants of type 2 diabetes in South Asia
10.1016/s2213-8587(18)30204-3 · 2018 · External reference
Utility of genetic risk scores in type 1 diabetes
10.1007/s00125-023-05955-y · 2023 · External reference
Development and validation of a type 1 diabetes multi-ancestry polygenic score
10.2337/db25-0772 · 2026 · External reference
Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis
10.2337/dc18-1785 · 2019 · External reference
